Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity

• References

• 1 Schömig A, Neumann FJ, Kastrati A. et al. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med 1996; 334: 1084-1089.
• 2 CURE Investigators. Clopidogrel in Unstable angina to prevent Recurrent Events trial Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 2001; 358: 527-533.
• 3 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
• 4 Bonello L, Paganelli F, Arpin-Bornet M. et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 05: 1630-1636.
• 5 Morel O, Viellard C, Faure A. et al. Platelet respon-siveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation. Ann Cardiol Angiol 2007; 56: 21-29.
• 6 Schwarz UR, Geiger J, Walter U et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
• 7 Geiger J, Teichmann L, Grossmann R et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51: 957-965.
• 8 Aleil B, Ravanat C, Cazenave JP. et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with thrombotic cardiovascular diseases. J Thromb Haemost 2005; 03: 85-92.
• 9 Barragan P, Bouvier JL, Roquebert PO. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
• 10 Blindt R, Stellbrink K, de Taeye A. et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
• 11 Frere C, Cuisset T, Quilici J. et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
• 12 Bonello L, Camoin-Jau L, Arques S. et al. Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study. J Am Coll Cardiol 2008; 51: 1404-1411.
• 13 Bonello L, Camoin-Jau L, Armero S. et al Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
• 14 TRITON-TIMI 38 Investigators. Pharmacody-namic assessment of platelet inhibition by prasu-grel vs. clopidogrel in the TRITON-TIMI 38 trial. . Eur Heart J 2009; 30: 1753-1763.
• 15 Serebruany V, Rao SV, Silva MA et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31: 227-235.